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Chen Ling1,2,*, Kanit Bhukhai3,*, Zifei Yin1,2,4,*, Mengqun Tan5, Mervin C. Yoder6, 
Philippe Leboulch3, Emmanuel Payen3 & Arun Srivastava1,2,7
We have reported that of the 10 commonly used AAV serotype vectors, AAV6 is the most efficient in 
transducing primary human hematopoietic stem/progenitor cells (HSPCs). However, the transduction 
efficiency of the wild-type (WT) AAV6 vector varies greatly in HSPCs from different donors. Here we report 
two distinct strategies to further increase the transduction efficiency in HSPCs from donors that are 
transduced less efficiently with the WT AAV6 vectors. The first strategy involved modifications of the viral 
capsid proteins where specific surface-exposed tyrosine (Y) and threonine (T) residues were mutagenized 
to generate a triple-mutant (Y705 + Y731F + T492V) AAV6 vector. The second strategy involved the use 
of ex vivo transduction at high cell density. The combined use of these strategies resulted in transduction 
efficiency exceeding ~90% in HSPCs at significantly reduced vector doses. Our studies have significant 
implications in the optimal use of capsid-optimized AAV6 vectors in genome editing in HSPCs.
Genetically-modified autologous hematopoietic stem/progenitor cells (HSPCs) transplantation is the most prom-
ising therapeutic strategy to treat inherited genetic diseases, such as β -globin disorders1, leukodystrophies2,3, 
severe combined immunodeficiency4, Wiskott-Aldrich syndrome5, as well as acquired diseases such as AIDS6. 
Recent remarkable progress in genome editing tools include zinc-finger nucleases (ZFNs), transcription activator 
like effector nucleases (TALENs), and the RNA-guided clustered regulatory interspaced short palindromic repeat 
(CRISPR)/Cas9 endonucleases. These targeted nucleases further expand the application of ex vivo editing of ther-
apeutic genes into patient HSPCs7. Most of these methods require the delivery of extracellular DNA into HSPCs, 
the efficiency of which is frequently sub-optimal. In the present study, we describe a novel, adeno-associated 
virus (AAV) vector-based DNA delivery strategy to overcome the current drawbacks that limit the clinical use of 
HSPCs gene editing methods.
The current drawbacks of HSPCs gene editing using viral methods such as chimeric adenoviral vectors, ret-
roviral vectors, or integrase-defective lentiviral vectors (IDLV) include inefficient gene delivery, cytotoxicity, or 
DNA insertion. For example in a phase I/II clinical trial, a self-inactivating lentiviral vector achieved genetic 
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modification in only 9–14% of blood cells after transplant2. Similarly, in laboratory, lentiviral transduction can 
produce no more than 22% transgene expression even in the presence of the best chemical helper8. Although 
it has now become feasible to achieve significantly higher transduction efficacy in HSPCs because of lentiviral 
vector optimization9 and good manufacturing process10, the high rate of stable transduction is also concomitant 
with a high vector genome copy number per cell, which, raises safety concerns because lentiviral genome, unlike 
the AAV genome, is associated with high risk of insertional mutagenesis. Non-integrative lentiviral vectors are 
safer but still limited by lower level of gene expression than other systems11. Cytotoxicity concerns also remains 
on transduced HSPCs. For example, the combination of the adenoviral vector and a potential enhancer, protein 
kinase C, resulted in > 25% gene disruption, however, it is less tolerated in HSPCs than in other cell types12. 
Theoretically, the presence of any DNA material may have a chance to insert into the host genome. Insertion is 
a potential problem as extended expression of the nuclease may increase off-targeting. In addition, the nature of 
viral-based vectors, such as lentiviral, retroviral, and adenoviral vectors, enhance the random insertional activities 
that may lead to altered gene expression. For example, in a recent clinical trial using retroviral vectors, > 140,000 
unambiguous integration sites and a polyclonal pattern of hematopoiesis were revealed in all patients, which led 
to acute leukemia in 7 of 10 patients13. However, editing for therapeutic purposes in HSPCs will be done with 
non-integrative vectors. Although the probability of IDLV vectors to integrate in a cell is much lower than for 
normal integrative lentiviral vectors, and AAV vectors have been shown to undergo integration, albeit at a much 
lower frequency, the rates of integration for IDLV and AAV vectors remain to be directly compared.
Although vectors based on AAV2 serotype have been used for transduction of primary human HSPCs, the effi-
ciency has been reported to be low14–16. Based on our initial studies, in which we mutagenized the surface-exposed 
tyrosine (Y) residues on AAV2 capsids, and observed a significant increase in their transduction efficiency17,18, 
the transduction efficiency of primary human HSPCs could be further increased with the capsid-modified AAV2 
vectors19. As additional AAV serotypes became available, we systematically evaluated the transduction efficiency 
of the 10 most commonly used AAV serotype vectors in primary human HSPCs, and observed that the AAV6 
serotype vectors were the most efficient20, and that the transduction efficiency of capsid-modified AAV6 vectors 
could be increased significantly21.
In our present studies, we describe two additive strategies to augment the transduction efficiency of AAV6 
serotype vectors in primary human CD34+ cells, as well as propose a hypothetical model to help explain the 
underlying molecular mechanism of the observed increase in transduction. Our studies have not only contributed 
to a broader understanding of the AAV-host cell interactions, but have also led to the development of novel AAV6 
serotype vectors for their optimal use in genome editing in primary human hematopoietic stem/progenitor cells.
Results
Our previous efforts have identified recombinant AAV serotype 6 (rAAV6) with high tropism for human 
HSPCs20,21. We have also reported that the transduction efficiency ranged between ~0–50% (n = 12 donors) 
for AAV2, and ~6–87% (n = 11 donors) for AAV6 in HSPCs, respectively15,20. Although we hypothesized that 
such a wide range of donor variation is due to different levels of expression of the putative receptors and/
or co-receptors on these cells, we were able to achieve significant increase in the transduction efficiency of 
both AAV2 and AAV6 vectors using site-directed mutagenesis of surface-exposed tyrosine (Y) residues. We 
therefore wished to examine whether the transduction efficiency of AAV6 vectors could be further improved 
by additional capsid modifications involving mutagenesis of surface-exposed serine (S) and threonine (T) resi-
dues, and various permutations and combinations thereof22. To this end, a number of such mutant capsids were 
generated, and self-complementary AAV6 (scAAV6) vectors containing a chicken beta actin promoter/CMV 
enhancer driving an enhanced green fluorescence protein gene (CBAp-EGFP) were produced as previously 
reported23. Using K562 cells, frequently used as a model for hematopoietic cell transduction studies, indicated 
that among all AAV6 capsid variants tested, a triple-mutant (TM) AAV6-Y705 + 731F + T492V (TM-AAV6) 
vector was identified as the most efficient (Fig. 1a). The transduction efficiency of the TM-AAV6 vectors was 
also consistently significantly higher than its wild-type (WT) counterpart not only in K562 cells, but also in 
primary human bone marrow-derived HSPCs obtained from a normal volunteer donor (Fig. 1b,c). Similar 
results were obtained with HSPCs obtained from one additional donor (Supplementary Table 1, Donor 2). No 
variability in expression levels under different transduction conditions was observed using flow cytometry or 
fluorescence microscopy.
During the course of these studies, we also observed that the transduction efficiency of the WT AAV6 vectors could 
be significantly increased if transductions were carried at high cell density, both at low and high multiplicities of infec-
tion (MOIs), in contrast to previously published studies, in which transductions were carried out at cell densities rang-
ing from 7.0 × 105–1.1 × 106 cells/ml14–16,19–21,24. The results, as analyzed by flow cytometry 48 hrs post-transduction, 
indicated that, compared to the conventionally used cell densities, increased cell density, up to 1.0 × 107 cells/ml, 
dramatically enhanced the scAAV6-mediated transgene expression, in both the EGFP-positivity and EGFP mean 
fluorescence intensity (Fig. 2a), presumably due to the increased probability of more efficient vector attachment to 
the cell receptor and/or co-receptor. Next, K562 cells were transduced with the optimized TM-scAAV6-CBAp-EGFP 
vectors either at low-density (1 × 106 cells/ml) or high-density (1 × 107 cells/ml). Whereas only ~25% of K562 cells 
were transduced at low-density, the transduction efficiency at high-density increased up to 77%, and the EGFP mean 
value increased to 160% (Fig. 2b,c). The enhancement of transgene expression also correlated with a significantly 
increased intra-cellular viral genome copy number (Fig. 2c), as determined by qPCR of total DNA isolated 2 hrs 
post-transduction25. Similar results were obtained with the TM-scAAV6 vectors expressing the Gaussia luciferase 
(Gluc) transgene (Fig. 2d), as well as when the optimized AAV2-CBAp-EGFP vectors containing the quadruple 
mutation (Y444 + 500 + 730F + T491V; QM-scAAV2) vectors, which we have previously identified to be the most 
efficient vector, albeit in human cell lines in vitro, and in murine hepatocytes in vivo26, were used (Fig. 2e). Similar 
results were also obtained when these serotype vectors were used to transduce HSPCs from a donor, which are 
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transduced extremely poorly under conventional conditions (Fig. 2f). The enhanced transgene expression medi-
ated by TM-scAAV6 vectors observed under high cell density conditions also correlated well with increased 
internalized vector genome copy number/cell (Fig. 2g) as well as with ssAAV6 vectors (Supplementary Fig. 1a).
To further corroborate our hypothesis, K562 cells were transduced and later concentrated or diluted. 
That the initial cell-cell contact was critical in achieving high-efficiency transduction, was further corrob-
orated by experiments in which cells were transduced at low-density, and subsequently pooled together 
and centrifuged to reach high-density, and conversely, cells were transduced at high-density, and soon 
after transduction, were diluted to low-density (Supplementary Fig. 2a). The elevated transduction was 
observed only under the latter condition (Supplementary Fig. 2b). The increased transduction efficiency 
at high-density also correlated well with the vector genomes entering the cells, as determined by qPCR 
analyses (Supplementary Fig. 1a). In the second set of experiments, a fixed number of K562 cells were 
infected with viral vectors in various volumes for 2 hrs and subsequently diluted in the same volume of 
2 ml (Supplementary Fig. 3a). Once again, the increased transduction efficiency was observed only under 
the condition of high cell density (Supplementary Fig. 3b,c), accompanied with a significantly increased 
intra-cellular viral genome copy numbers (Supplementary Fig. 3d).
We next extended these studies to include two additional human hematopoietic cell lines, M07e and Raji, 
which express low to extremely low levels of HSPG, the primary receptor for AAV2, and consequently, are 
Figure 1. Transduction efficiency of various capsid-modified AAV6 vectors in human hematopoietic 
cells. (a) Human erythroleukemia cells, K562, were either mock-transduced, or transduced with the wild-
type (WT) or various indicated capsid-modified scAAV6-CBAp-EGFP vectors at an MOI of 3,000 vgs/cell. 
Transgene expression was analyzed by flow cytometry 48 hrs post-transduction. (b) Primary human bone 
marrow-derived CD34+ cells from a single individual donor were transduced in triplicate with the WT or the 
Y705 + 731F + T492V triple-mutant (TM) scAAV6-CBAp-EGFP vectors at MOIs of 3,000 or 10,000 vgs/cell. 
Transgene expression was analyzed by flow cytometry 48 hrs post-transduction. (c) Mean fluorescence intensity 
of transgene expression. Error bars represent standard deviations (SD).
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transduced extremely poorly by AAV2 vectors27. As can be seen in Supplementary Fig. 4a,b, under the condition 
of high cell density, significantly enhanced transduction of M07e cells, but not Raji cells, was observed, since 
M07e cells do express high levels of AAV2 co-receptor, fibroblast growth factor receptor 1 (Supplementary Fig. 
4c), but not Raji cells, which express undetectable levels of both HSPG and FGFR127. To address the possibility 
whether alternative receptors/co-receptors were being used under the condition of high cell density, K562 cells 
were transduced with scAAV2 vectors in the absence or the presence of heparin, which is known to compete 
for AAV2 cellular entry. As can be seen in Supplementary Fig. 4d,e, heparin at 5 μ g/ml significantly reduced the 
transduction efficiency of scAAV2 vectors under the condition of high cell density for each of the cell types tested. 
These results strongly suggest that the putative receptors/co-receptors for viral entry remain unaltered under the 
condition of high cell density.
We further evaluated the efficacy of AAV vector-mediated transduction of primary HSPCs derived from bone 
marrow (BM) as well as from umbilical cord blood (CB). BM-derived CD34+ cells from individual donors (or 
a mixture from 10 donors) were purchased from a commercial source (AllCells, LLC, Alameda, CA, USA), and 
were used to transduce with different scAAV-CBAp-EGFP vectors at an MOI of 10,000 vgs/cell without fetal 
bovine serum (FBS). Transgene expression was evaluated by flow cytometry 48 hrs post-transduction. As shown 
in Supplementary Table 1, consistent with our previously published studies, whereas scAAV6 vectors transduced 
human HSPCs more efficiently than scAAV2 vectors, capsid modification on both vectors further enhanced 
their transduction efficiency. The transgene expression at high cell density was consistently higher than that at 
Figure 2. Transduction efficiency of AAV vectors in human hematopoietic cells at various cell densities. 
(a) K562 cells were transduced at various indicated cell densities at MOIs of 3,000 or 30,000 vgs/ml with WT 
scAAV6-CBAp-EGFP vectors. Transgene expression was analyzed by FACS 48 hrs post-transduction. (b) K562 
cells were also transduced at low (1 × 106/mL) or high (1 × 107/mL) cell densities with 3,000 vgs/cell of TM 
scAAV6-CBAp-EGFP vectors, and transgene expression and mean fluorescence intensity were determined as 
described above. (c) The vector genome copy numbers/cell were determined 2 hrs post-vector transduction by 
qPCR and data were normalized to β -actin DNA copy number. (d) K562 cells were transduced at low or high 
cell densities with TM-scAAV6-CBAp-Gluc vectors, and luciferase expression was determined in the culture 
supernatants. (e) K562 cells were transduced at low or high cell densities with QM-scAAV2-CBAp-EGFP 
vectors, and transgene expression and mean fluorescence intensity were determined as described above.  
(f) Primary human bone marrow-derived CD34+ cells were transduced at low or high densities with indicated 
AAV6 or AAV2 vectors, EGFP-expressing cells were visualized under a fluorescence microscope 48 hrs post-
transduction. (g) The vector genome copy numbers/cell were determined as described above.
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low cell density. The increased transduction efficiency in human HSPCs at high cell density also correlated with 
a significantly increased intra-cellular viral genome copy number 2 hrs post-viral transduction (Supplementary 
Fig. 1b). However, the extent of transgene expression declined over time, and in none of the cell populations 
tested, the viral genome copy number was above the detection limit of qPCR 14 days post-transduction (data 
not shown). Similar results were obtained with CB-derived CD34+ cells, except that the overall transduction effi-
ciency was consistently higher than that in BM-derived CD34+ cells. In the first set of experiments, CD34+ cells 
were transduced at low and high cell densities with TM-scAAV6-CBAp-EGFP and TM-ssAAV6-CBAp-EGFP 
vectors at an MOI of 20,000 vgs/cell without FBS, followed by switch to FBS-containing expansion medium 
and cultured for 10 days, and transgene expression was evaluated by FACS at 4 and 10 days post-transduction 
(Fig. 3a). It is evident that at day 4, scAAV6 vectors were more efficient than ssAAV6 vectors, but at high cell 
density, there was only a modest enhancement in EGFP-positivity. Again, the transgene expression diminished 
over time. In the second set of experiments, CB-derived CD34+ cells were transduced at low and high cell den-
sities with TM-scAAV6-CBAp-EGFP vectors as described above, except that at day 10, cells were switched to an 
erythroid differentiation medium and cultured for 4 additional days. EGFP expression was determined by flow 
cytometry at day 4, day 7, day 10, and day 14 (Fig. 3b). As can be seen, once again, at day 4, scAAV6 vectors were 
more efficient than ssAAV6 vectors. At high cell density, there was a modest enhancement in EGFP-positivity, 
Figure 3. Transduction efficiency of TM-ssAAV6 and TM-scAAV6 vectors in primary human CD34+ 
cells. (a) Primary human cord blood-derived CD34+ cells were either mock-transduced, or transduced at 
day 0 at low (0.5 × 106 cells/ml,) or high (1 × 107 cells/ml) cell density with 20,000 vgs/cell of the indicated 
AAV6 vectors in serum free XVIVO20 medium. Two hrs later, cells were diluted to 5 × 105 cells/mL and 
switched to the expansion medium (IMDM + FBS + SCF + IL3 + Epo+ Dexamethasone + β -estradiol + β 
-mercapthoethanol). EGFP expression was determined by flow cytometry at day 4 and day 10 post-
transduction. (b) Following mock-transduction, or transduction of CD34+  cells as described above, cells 
were switched to the expansion medium for 10 days, and cultured in an erythroid differentiation medium 
(IMDM + BSA + Insulin + Transferrin + Epo) for an additional four days. EGFP expression was determined 
by flow cytometry. (c,d) Vector-transduced CD34+ cells cultured in the differentiation medium were stained 
with hCD36-PE and hGlycophorin A−FITC and analyzed by flow cytometry for the following: non-erythroid 
(CD36−/glycoA−), and erythroid cells (CD36+/GlycoA+) from day 10 to day 14.
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but transgene expression diminished over time, and eventually resulted in less than 1% EGFP-positive cells 
14 days post-transduction, which is within the variation of mock-transduced cells (0.14–1.84%), corroborat-
ing again the loss of vector genome, as determined by qPCR assays described above, and hence, lack of stable 
integration in HSPCs. Staining with hCD36-PE and hGlycophorin A-FITC showed the typical induction of 
erythroid cell differentiation, which was unaltered following vector transduction (Fig. 3c,d). At the end of 
the culture period, most cells were GlycoA+, indicating that none of erythroid-differentiated cells expressed 
the transgene.
Discussion
Although AAV vectors have been successfully used in transducing a wide variety of cells and tissues, primary hemato-
poietic stem/progenitor cells (HSPCs) have proven to be particularly difficult to transduce despite sustained efforts by 
us and others spanning nearly three decades. However, most of those studies were carried out with AAV2 serotype 
vectors. With the subsequent availability of a number of additional serotypes, we were able to identify AAV6 as the 
most efficient in transducing HSPCs20,21. Despite this advance, we also observed a significant donor-variation ranging 
between 6–87%. Although this could be due to differences in various steps in the life cycle of AAV6 vectors in HSPCs 
from different donors, we chose to focus on the initial virus-host cell interaction, primarily involving the putative cel-
lular receptors and co-receptors for AAV6. Although epidermal growth factor receptor (EGFR) has been identified to 
be the cellular receptor for AAV628, those studies were not performed with hematopoietic cells. In addition, we have 
previously reported that K562 cells, which are known to lack expression of EGFR, are efficiently transduced by AAV6 
vectors, and that pre-treatment of primary human CD34+ cells with EGF has no effect on the transduction efficacy of 
AAV6 vectors21. Thus, the precise identity of the receptor and co-receptor for AAV6 in HSPCs remains elusive. Based 
on our observation of significantly increased transduction under the conditions of high cell density, we hypothesized 
that a close cell-cell contact facilitates more efficient vector binding and entry into cells grown in suspension culture, 
presumably because of the close proximity of the receptor and the co-receptor on neighboring cells, and AAV6 vec-
tor bound to the receptor on one cell utilizes the co-receptor on the neighboring cell to gain entry in the latter, and 
vice versa, thus leading to increased transduction. Indeed, using AAV2 vectors, for which the cellular receptors and 
co-receptors have been well characterized, we were able to corroborate our hypothesis to a certain extent.
Clearly, additional studies are warranted, but we believe that our data have revealed a novel mechanism, which 
AAV vectors exploit to gain entry into target cells. For example, adherent cells such as HEK293, are readily trans-
duced by AAV2 vectors because these cells abundantly express the cell surface receptor, heparan sulfate proteoglycan 
(HSPG), and one of the co-receptors, human fibroblast growth factor receptor 1 (FGFR1) for AAV2. However, K562 
cells are not transduced as efficiently, although these cells, grown in suspension, express both HSPG and FGFR1 only 
at modestly lower levels. We reasoned that the lack of proximity of HSPG and FGFR1 on K562 cells might account 
for the suboptimal transduction of these cells, and hypothesized that if the transduction was performed at high cell 
density, presumably allowing for HSPG on one cell to come in close proximity to FGFR1 on the neighboring cell, 
then AAV2 bound to HSPG on one cell could utilize FGFR1 on the neighboring cell to gain entry in the latter, and 
vice versa, thus leading to increased transduction which was observed experimentally.
We also believe that our studies described here have practical utility. For example, recent development of targeted 
nucleases provides a means to achieve precise genome editing in stem cells, including human HSPCs. However, 
all these strategies require the delivery of DNA materials. Although the expression of targeted nucleases could be 
achieved by mRNA delivery, a homologous donor DNA template must also be introduced. An exception is the 
CRISPR/Cas9 system that utilizes a short guide RNA and RNA-guided nuclease29. Nevertheless, the majority of 
research still uses DNA delivery systems, such as plasmids and viral vectors to express the short guide RNA, due 
to the low efficiency of RNA delivery in human HSPCs30. Thus, the off-target activities as well as random inser-
tion of the delivered DNA constitute significant safety hurdles to overcome31. While our current studies were in 
progress, three independent groups not only corroborated our previously published studies20,21, but also reported 
successful transduction of primary human CD34+ cells using the WT AAV6 vectors for genome editing32–34, except 
that MOIs ranging from 100,000–200,000 vgs/cell were used to achieve ~40–55% transduction efficiency. Using 
capsid-optimized AAV6 vectors and transduction conditions described here, at an MOI of 20,000 vgs/cell, transduc-
tion efficiency exceeding 90% can now routinely be achieved, which is significantly higher than any known vector 
system currently in use. Thus, our studies have significant implications in highly efficient gene therapy and genome 
editing with capsid-optimized AAV6 vectors involving primary human HSPCs.
Methods
Cells and reagents. Human embryonic kidney cell line, HEK293, and human erythroleukemia cell line, 
K562, were purchased from the American Type Culture Collection (Manassas, VA). The human lymphoblastoid 
cell line, Raji, and the human megakaryocytic leukemia cell line, M07e, were obtained from Drs Z.A. Brahmi 
and H.E. Broxmeyer (Indiana University School of Medicine, Indianapolis, IN), respectively. Monolayer cul-
tures of HEK293 were maintained in Dulbecco’s-modified Eagle’s medium (DMEM), and suspension cultures 
of K562, M07e, and Raji were maintained in Iscove’s-modified Dulbecco’s medium (IMDM) supplemented with 
10% fetal bovine serum (FBS) and 1% antibiotics (Lonza, Basel, Switzerland). Primary human bone marrow-de-
rived CD34+ cells were purchased from AllCells (Alameda, CA). Human cord blood cells were collected by the 
Assistance Publique – Hôpitaux de Paris (AP-HP), according to French bioethics law 2011-814. The research 
project for cell usage was approved by the scientific council of Fondation Générale de Santé (FGDS) and AP-HP. 
Written informed consents were obtained from mothers of the newborn.
AAV vector production. The ssAAV and scAAV plasmids containing the CBAp-EGFP transgene expression 
cassette have been described previously35. All AAV vectors were produced using the polyethelenimine-mediated 
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triple-plasmid transfection method36. Briefly, HEK293 cells (Agilent Technologies) were harvested 72 hrs 
post-transfection, and lysed by 3 rounds of freeze-thaw, and digested with Benzonase (Invitrogen, Grand Island, 
NY). Cell debris was removed by centrifugation. AAV vectors were purified by iodixanol (Sigma, St. Louis, MO) 
gradient ultracentrifugation, followed by ion exchange chromatography using HiTrap SP/Q HP columns (GE 
Healthcare, Piscataway, NJ), washed with phosphate-buffered saline (PBS) and concentrated by centrifugation 
using centrifugal spin concentrators with 150 K molecular weight cutoff. Titers were determined by Quantitative 
real-time PCR assays as previously described37.
AAV transduction. The culture conditions for K562, Raji, and M07e cell have been described previously27. 
AAV transductions were performed in FBS-free medium for 2 hrs. Cells were then switched to FBS-containing 
medium for growth. Primary human HSPCs were purchased from AllCells Technologies (Emeryville, CA). Cord 
blood CD34+ cells were thawed and immediately transduced with AAV vectors at 20,000 vgs/cell in serum free 
XVIVO20 medium. Two hrs post-transduction, cells were switched to the expansion medium (IMDM, FBS, 
SCF, IL3, Epo, Dexamethasone, β -estradiol, β -mercapthoethanol) and grown at 5 × 105 cells/mL. At day 10, cells 
were switched to the erythroid differentiation medium (IMDM, BSA, Insulin, Transferrin, Epo). All transgene 
expressions were determined either by fluorescence microscopy or by flow cytometry, as described previously20,21.
Erythroid expansion of CD34+ cells. Ten days after culturing in the expansion medium, cells were stained 
with hCD36-PE and hGlycophorin A-FITC showing the typical profile of expanded cells in this amplification 
medium: non-erythroid (CD36−/glycoA−), and erythroid cells (immature: CD36+/GlycoA−; early mature: 
CD36high/GlycoAmed and late mature: CD36med/glycoAhigh). Stained cells were subjected to flow cytometry assays.
Viral genome copy number determination. Total cellular DNA was isolated using the PureLink® 
Genomic DNA Kits (ThermoFisher Scientific, MA) in accordance with the manufacturer’s protocol. DNA con-
centration was determined by Nanodrop (ThermoFisher Scientific, MA). One hundred ng of DNA from each 
sample was used as the template material for quantitative real-time PCR. The EGFP vector genome copy numbers 
were determined and normalized by the results of human β -actin gene in each sample.
Heparin competition assays. Cells were transduced with scAAV2-CBAp-EGFP vectors at an MOI of 
5,000 vgs/cell. Vectors were premixed with vehicle control or 5 μ g/ml heparin sodium salt (Sigma, St. Louis, MO). 
Cells were switched to heparin-free complete DMEM 2 hrs post-transduction and then were analyzed for EGFP 
levels by flow cytometry 72 hrs post-transduction.
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